Following the development of the Canadian Integrated and Comprehensive Care Standards for Inherited Bleeding Disorders (Second Edition) in 2020, the Canadian Inherited Bleeding Disorder Standards...
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...
Each year the CHS honours individuals who have made a significant contribution to improving the quality of life of people with bleeding disorders. The 2023...
HIV Justice News published the following on October 28: “The past two weeks has seen some important HIV Justice advances in three countries – Canada,...